Suppr超能文献

微卫星不稳定的结直肠癌术后血浆中的肿瘤源性突变

Tumor-derived mutations in postoperative plasma of colorectal cancer with microsatellite instability.

作者信息

Li Liren, Zhou Wenhao, Li Qian, Li Pansong, Yang Ling, Xia Xuefeng, Yi Xin, Wan Desen

机构信息

State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, P. R. China; Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China.

Geneplus-Beijing, Beijing 102206, P. R. China.

出版信息

Transl Oncol. 2021 Jan;14(1):100945. doi: 10.1016/j.tranon.2020.100945. Epub 2020 Nov 12.

Abstract

The mutation in postoperative plasma (molecular residues) was an independently prognostic factor in colorectal cancer (CRC). The status of postoperative plasma mutation of microsatellite instability (MSI) CRC has not been systematically examined. In this study, we enrolled 30 MSI and 46 microsatellite stability (MSS) CRCs, and performed next generation sequencing on surgical tissues, postoperative plasma, and plasma during follow-up. Compared with MSS, MSI tumors had dissimilar genomic profiles, higher tumor mutation burden (TMB), and more frameshift mutations. In the postoperative plasma, more MSI CRCs were detected with tumor-derived mutations (77% in MSI vs 33% in MSS, p < 0.001). The numbers of postoperative mutations were proportional to MSI tissues (Spearman r = 0.47, p = 0.023), while not for MSS. More proportion of postoperative plasma samples of MSI CRCs harbored frameshift mutations than MSS (p = 0.007). For the follow-up plasma, 93% (14 out of 15) MSI CRCs harbored tumor-derived mutations; 33% (4/12) MSS were mutation-positive, lower than MSI (p = 0.003). Thus, considering that MSI CRC had extremely distinct mutational characteristics in tumor and postoperative plasma compared with MSS CRC, we propose that the prognostic value of molecular residue identification in postoperative plasma needs to be independently evaluated in MSI and MSS CRCs.

摘要

术后血浆中的突变(分子残留)是结直肠癌(CRC)的独立预后因素。微卫星不稳定(MSI)CRC术后血浆突变状态尚未得到系统研究。在本研究中,我们纳入了30例MSI CRC和46例微卫星稳定(MSS)CRC,并对外科手术组织、术后血浆及随访期间的血浆进行了二代测序。与MSS相比,MSI肿瘤具有不同的基因组图谱、更高的肿瘤突变负荷(TMB)和更多的移码突变。在术后血浆中,检测到更多MSI CRC存在肿瘤源性突变(MSI中为77%,MSS中为33%,p<0.001)。术后突变数量与MSI组织呈正相关(Spearman r = 0.47,p = 0.023),而与MSS无关。MSI CRC术后血浆样本中携带移码突变的比例高于MSS(p = 0.007)。对于随访血浆,93%(15例中的14例)MSI CRC存在肿瘤源性突变;33%(12例中的4例)MSS为突变阳性,低于MSI(p = 0.003)。因此,鉴于与MSS CRC相比,MSI CRC在肿瘤和术后血浆中具有极其不同的突变特征,我们建议在MSI和MSS CRC中独立评估术后血浆中分子残留鉴定的预后价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afca/7674603/a0b6f127382d/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验